Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

News Release

WAVE Life Sciences Announces Pricing of Initial Public Offering

November 11, 2015 at 6:30 AM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 11, 2015-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a preclinical biopharmaceutical company using its proprietary chemistry platform to design, develop and commercialize a broad pipeline of first-in-class or best-in-class stereopure nucleic acid therapeutics candidates, today announced the pricing of its initial public offering of 6,375,000 ordinary shares at a price to the public of $16.00 per share. In addition, WAVE Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 956,250 ordinary shares. The ordinary shares are expected to begin trading on The NASDAQ Global Market on November 11, 2015 under the symbol “WVE”.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151111005369/en/

Paul Bolno, President and CEO, WAVE Life Sciences (Photo: Business Wire).

Paul Bolno, President and CEO, WAVE Life Sciences (Photo: Business Wire).

Jefferies and Leerink Partners are acting as joint book-running managers for the offering. JMP Securities and SunTrust Robinson Humphrey are acting as co-managers for the offering.

The offering is being made only by means of a prospectus. When available, copies of the final prospectus related to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com; or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: (800) 808-7525, ext. 6142, e-mail: syndicate@leerink.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on November 10, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Source: WAVE Life Sciences Ltd.

Feinstein Kean Healthcare
Jessi Colund, 952-649-8600